PERSPECTIVE article
Front. Neurol.
Sec. Movement Disorders
Brain Fog in Parkinson's Disease: Unraveling Mechanisms and Measuring Impact
Provisionally accepted
- 1Department of Educational Psychology, College of Education and Human Development, Texas A&M University, College Station, Texas, United States
- 2Ventus Therapeutics U.S., Inc., Waltham, MA, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Inconsistent colloquial and professional uses of the term "brain fog" have undermined the potential for empirical study of this symptom complex, and there is no consensus about how to diagnose or treat it. Yet brain fog is frequently reported by patients with post-acute sequelae of SARS-CoV-2 (PASC) and other chronic conditions, often presenting as cognitive difficulties such as memory issues and attention deficits, accompanied by central fatigue and sometimes depression. This symptom complex is also common in Parkinson's disease (PD). One objective of this article is to propose a theoretical model that conceptualizes brain fog in PD in terms that can guide its measurement and treatment. Neuroinflammation, dopaminergic dysfunction, and immune system interactions are examined as potential mechanisms. We present the Fatigue and Altered Cognition Scale (FACs), a patient-report tool designed to assess brain fog in clinical and research settings that has been validated in traumatic brain injury and PASC. Proper diagnosis and monitoring of brain fog are important because early research suggests that existing medications, such as methylphenidate, and natural substances, such as carnosic acid, have the potential to alleviate its symptoms. Ongoing research is crucial to establish a clear definition of brain fog and identify effective treatments in PD and other neurodegenerative disorders.
Keywords: brain fog, Parkinson's disease, Neuroinflammation, Dopamine, Neuroimmunomodulation, Fatigue, cognitive dysfunction, Fatigue and Altered Cognition Scale
Received: 04 Feb 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Elliott, Valencia, Chen and Matta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Andre Matta, amatta@ventustx.co
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.